A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS-6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance.

A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult Female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis)

A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent
and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

The mission of Desert AIDS Project/D.A.P. is to enhance and promote the health and well-being of our community.

Explore 311,636 research studies in all 50 states and in 209 countries. ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

Obesity and Healthy Thinking Study This study is being done to learn if Egrifta may improve brain function in HIV positive people with abdominal obesity, which increases the risk for impaired thinking. Call Rod Hagan at 760.507.3321

People living with HIV are 50–100% more likely to develop heart disease (including heart attack and stroke) than people without HIV. ​ REPRIEVE is a clinical research trial exploring long-term prevention of heart disease among people living with HIV. Call: 1-877-29-HEART Leah Lane 760-834-7949

Clinicians at Eisenhower Medical Center continue to take part in groundbreaking research, including: interventional cardiology, orthopedics, novel biotherapies in oncology, targeted therapies base on molecular profile of cancer, early detection of cancer via specialized imaging, drugs aimed at improving survival of HIV patients, and use of integrative therapies to reduce side effects related to cancer treatment.

Recruiting participants who have a current viral load >400 copies : Investigating PRO 140 subcutaneous injection once weekly combine with OBT in treatment experienced patients. ​

The GALACTIC-1 study will research a potential study drug that could offer benefit to patients with IPF. Thank you for considering participation in this trial. ​